E N D
1. San Francisco VA Medical Center and Hepatitis C Alexander Monto, M.D.
Assistant Professor in Medicine, University of California, San Francisco
Gastroenterology/Hepatology, San Francisco Veterans Affairs Medical Center
May 10, 2010
2. Prevalence- HBV, HCV, HIV
3. Hepatitis C at SFVAMC Estimated prevalence of chronic HCV infection:
USA: 1-2 %
Veterans using VA: 5 %
SFVAMC point-prevalence: 17.7%
Briggs ME et al, Hepatology 2001;34:1200
>80% of patients in SFVAMC Liver Clinic have hepatitis C
4. Patients in VA Care with HCV:Cirrhosis and HCC FY 2005-2007
5. Hepatitis C Infection: Disease Progression
6. Anti-Hepatitis C Therapy Current therapies:
1) Interferon Alpha-2b, 3M.U. sq tiw + Ribavirin 1000-1200mg po qd in divided doses (Rebetron)
2) PEG-Interferon Alpha-2b 1.5 mcg/kg sq qwk + Ribavirin 1000-1200mg po qd (PEG-INTRON + Ribavirin)
3) PEG-Interferon Alpha-2a 180 mcg sq qwk + Ribavirin 1000-1200mg qd (PEGASYS + Ribavirin)
www.hepatitis.va.gov
7. PROVE 1 and 2: Telaprevir Results Treatment-Naďve Genotype 1-Infected Patients
8. What Does the VA Offer: HCV Detection, Tx, Care Testing VA patients who have risk factors for having hep. C was a performance measure several years ago- led to markedly increased detection (HCV Ab+)
All honorably discharged U.S. military veterans are eligible for care in VA
Most VA patients receive full care without copays: HCV treatment, liver transplant, etc.
Copays for some medications
9. Unique Needs of Veterans: HCV HCV very prevalent among Vietnam-era veterans (6-8%)
Longstanding infection, so now many complications of cirrhosis: HCC, liver failure
PTSD, substance use
Social support
10. Lessons Learned/Service Gaps Layers of testing, follow-up in all patients with risk factors for HCV
HCV therapy is very labor-intensive
Access to specialty care is important (HCV treatment, cirrhosis management)
Housing, getting to SFVA: obstacles
11. Interacting with Mayors SF Hepatitis C Task Force SFVA is here to provide comprehensive support to patients who qualify
We will be happy to have visitors to learn about HCV therapy or cirrhosis management
alex.monto@ucsf.edu